Industry Newsendocrinologyclinical trialspalsonifycrinetics pharmaceuticals
Crinetics Gains Analyst Upgrades, Strong Trial Results
5.0
Crinetics Pharmaceuticals on Jan. 12 received a Buy upgrade from Goldman Sachs (Richard Law) with a $67 target after trial results showed a 67% reduction in A4 in Cohort 4 and sustained androgen reductions in seven of eight participants despite glucocorticoid dose cuts. Citizens slightly lowered its $105 target while keeping Outperform; analysts cited Palsonify’s positive early experience and preliminary Q4 net product revenue above $5 million.
Key Points
- 1Reports show 67% A4 reduction in Cohort 4, with seven of eight patients maintaining androgen reductions.
- 2Analysts upgraded ratings citing replicated trial outcomes and positive early commercial signals for Palsonify.
- 3Monitor regulatory progress, sales traction, and upcoming cohorts to assess commercial and clinical viability.
Scoring Rationale
Moderate investor and clinical relevance from replicated trial data, offset by niche scope and promotional, non-peer-reviewed reporting.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
